Abstract:
:Founded in 2009 and headquartered in Glasgow, Scotland, UK, Sistemic Ltd has developed from a thought in the minds of four scientists into a company working globally to play its part in delivering the exciting opportunities for improvements in human health presented by cell therapies and regenerative medicine products (jointly referred to as the CT industry). Sistemic is now working in all corners of the world with some of the industry's leading companies to ensure that the products that they are developing, which will undoubtedly change the way we treat some of the major diseases and conditions currently placing a large burden on healthcare systems, including diabetes, dementia and cardiovascular disease, are as safe and efficacious as possible. Sistemic is also working to ensure that these products can be produced at a cost that will not lead to potentially transformational treatments being an additional financial burden on our already overburdened healthcare systems. Sistemic is using its revolutionary and IP-protected SistemQC™ (UK) technology to enhance understanding of characterization, process optimization and potency of CT products. The company is using the diagnostic power of miRNAs, a set of approximately 2000 ncRNAs that regulate a large percentage of the total gene expression of a cell. miRNAs are often present in a cell- and tissue-specific way that, at least in some cases, accounts for the phenotypic differences between cell types. These differences in miRNA expression can be interpreted by the miRNA profile and it is interpreting the instructive power of these profiles that underpin Sistemic's knowledge bases, giving CT companies a more comprehensive understanding of their cell populations with respect to their identity and functional capabilities. This knowledge is being used by companies to characterize, process, optimize and assess the efficacy of cell products.
journal_name
Regen Medjournal_title
Regenerative medicineauthors
Reid Jdoi
10.2217/rme.13.58subject
Has Abstractpub_date
2013-09-01 00:00:00pages
549-52issue
5eissn
1746-0751issn
1746-076Xjournal_volume
8pub_type
杂志文章abstract::Tissue regeneration specialist company Organogenesis Inc. was one of the first biotech companies formed. Incorporated in 1985, the company was originally a spin-off from a research program at MIT. For the first 10-15 years, Organogenesis was heavily research based, but then gradually moved into development. The compan...
journal_title:Regenerative medicine
pub_type: 面试
doi:10.2217/17460751.1.2.169
更新日期:2006-03-01 00:00:00
abstract::Aim: Cell repopulation of tissue-engineered vascular grafts (TEVGs) from decellularized arterial scaffolds is limited by dense concentric tunica media layers which impede cells migrating radially between the layers. We aimed to develop and validate a new microneedle device to modify decellularized carotid arteries wit...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme-2019-0011
更新日期:2019-11-01 00:00:00
abstract:AIM:This study presents an interim safety and feasibility analysis of the REGENERATE-IHD randomized controlled trial, which is examining the safety and efficacy of three different delivery routes of bone marrow-derived stem cells (BMSCs) in patients with ischemic heart failure. METHODS & RESULTS:The first 58 patients ...
journal_title:Regenerative medicine
pub_type: 杂志文章,随机对照试验
doi:10.2217/rme.14.3
更新日期:2014-05-01 00:00:00
abstract::Regenerative medicine is an evolving, cross-disciplinary, international field that, as a result, uses terms that are either not widely understood, or may have a number of different meanings. Many stakeholders have identified this lack of clarity as a potential barrier to effective communication within the field. To ad...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme.09.34
更新日期:2009-07-01 00:00:00
abstract::Biocompatibility is key to the performance of any material in a biological environment. This review outlines current opinion on the factors that lead to biocompatibility and focuses on the interactions that occur at the interface between material and environment. The sequence of events, from protein adsorption, cell a...
journal_title:Regenerative medicine
pub_type: 杂志文章,评审
doi:10.2217/17460751.1.6.789
更新日期:2006-11-01 00:00:00
abstract::Advances in directed differentiation of human embryonic stem cells (hESCs) toward cardiac lineages have generated much interest within the myocardial therapy field. Beyond the promise that hESCs would provide a supply of new cardiomyocytes to the damaged heart, recent studies have also shown that paracrine effects of ...
journal_title:Regenerative medicine
pub_type: 杂志文章,评审
doi:10.2217/rme.12.46
更新日期:2012-09-01 00:00:00
abstract::The determinants of adoption of regenerative medicine therapies are currently poorly understood. This study aims to draw comparison between the UK and Canada in terms of factors likely to affect healthcare adoption of future regenerative therapies in ophthalmology. Conducting semi-structured interviews with senior oph...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme.14.82
更新日期:2015-05-01 00:00:00
abstract::We present a case of an 18-year-old with a 2-year history of buttock pain who failed extensive treatment for a perceived hamstring strain. Upon evaluation, he was diagnosed with an ischial tuberosity nonunion avulsion fracture. The patient underwent bone grafting via an ultrasound guided leukocyte rich platelet-rich p...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme-2018-0071
更新日期:2019-05-01 00:00:00
abstract::Aim: We aim to show that the use of nondigested micro-fragmented adipose tissue (MFat™, Lipogems®) is a viable alternative for treatment of joint pain and inflammation associated dysfunction in shoulder osteoarthritis (OA). Materials & methods: A total of 25 subjects with OA received an injection of MFat™ and were fol...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme-2020-0069
更新日期:2020-10-01 00:00:00
abstract::Dr Jane Lebkowski joined Geron Corporation in 1998 and is currently Senior Vice President and Chief Scientific Officer of the Regenerative Medicine Division. Dr Lebkowski heads Geron's human embryonic stem cell program, and is responsible for all research, preclinical development, product development, manufacturing an...
journal_title:Regenerative medicine
pub_type: 面试
doi:10.2217/rme.09.49
更新日期:2009-09-01 00:00:00
abstract::Mesenchymal stem cells (MSCs) have tremendous potential for regenerative medicine, and have been researched for the treatment of cardiovascular diseases. MSCs are a promising cell type because of their ease of isolation and expansion, their multipotency and their low immunogenicity. However, in order to fully utilize ...
journal_title:Regenerative medicine
pub_type: 杂志文章,评审
doi:10.2217/17460751.3.6.877
更新日期:2008-11-01 00:00:00
abstract::The ankle degeneration ranging from focal osteochondral lesions to osteoarthritis can cause a total joint function loss. With rising life expectancy and activity of the patients, various regenerative therapies were introduced aiming to preserve the joint function via the induction of cartilage and bone repair. Here, b...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme-2017-0104
更新日期:2018-03-19 00:00:00
abstract:AIM:Glucotoxicity obstructs pancreatic differentiation from adult stem cells. The aim was to develop a novel protocol for differentiation of dental pulp stem cells (DPSCs) into pancreatic β cells and determine the effect of H2S on glucotoxicity. MATERIALS & METHODS:DPSCs were differentiated with media containing 5.5 o...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme-2016-0142
更新日期:2017-03-01 00:00:00
abstract::Parkinson's disease and Alzheimer's disease are the most common neurodegenerative diseases in the elderly population. Given that age is the most important risk factor in these diseases, the number of patients is expected to rise dramatically in the coming years. Therefore, an effective therapy for these diseases is hi...
journal_title:Regenerative medicine
pub_type: 杂志文章,评审
doi:10.2217/17460751.2.4.425
更新日期:2007-07-01 00:00:00
abstract::Probably the most serious problem facing the field of regenerative medicine today is the challenge of effective translation and development of viable stem cell-based therapies. Particular concerns have been raised over the growing market in unproven cell therapies. In this article, I explore recent developments in the...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme-2017-0065
更新日期:2017-10-01 00:00:00
abstract::Diabetes mellitus represents a global epidemic affecting over 350 million patients worldwide and projected by the WHO to surpass the 500 million patient mark within the next two decades. Besides Type 1 and Type 2 diabetes mellitus, the study of the endocrine compartment of the pancreas is of great translational intere...
journal_title:Regenerative medicine
pub_type: 杂志文章,评审
doi:10.2217/rme.12.70
更新日期:2012-11-01 00:00:00
abstract::Finding solutions for patients with unmet needs is at the heart of Genzyme's innovative medical research. While small molecules and enzyme-replacement therapies have made significant strides in improving patients' quality of life and expectancy, the solutions to many conditions, such as heart disease or CNS diseases, ...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/17460751.2.1.95
更新日期:2007-01-01 00:00:00
abstract::Cord blood platelet gel is prepared by activation of coagulation in a platelet concentrate obtained from cord blood. During the process of clot formation, platelet alpha-granules release growth factors that promote tissue repair. However, in the form of gel, it is not possible to inject it into small, narrow and deep ...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme-2019-0074
更新日期:2020-01-01 00:00:00
abstract::Multipotent mesenchymal stromal cells (MSCs) hold tremendous promise for tissue engineering and regenerative medicine, yet with so many sources of MSCs, what are the primary criteria for selecting leading candidates? Ideally, the cells will be multipotent, inexpensive, lack donor site morbidity, donor materials should...
journal_title:Regenerative medicine
pub_type: 杂志文章,评审
doi:10.2217/rme.10.98
更新日期:2011-01-01 00:00:00
abstract::In June 2013, the US Supreme Court ruled that naturally occurring genes were unpatentable in the case Association for Molecular Pathology v. Myriad Genetics. Up until this decision, Myriad Genetics was the only company in the USA that could legally conduct diagnostic testing for BRCA1 and 2, genes that are linked to f...
journal_title:Regenerative medicine
pub_type: 杂志文章,评审
doi:10.2217/rme.13.93
更新日期:2014-03-01 00:00:00
abstract::Induced pluripotent stem (iPS) cells offer tremendous opportunity for the creation of autologous cellular therapies, in which gene correction or the avoidance of immune response issues are desirable. In addition, iPS cells avoid the ethical concerns raised by the sourcing of human embryonic stem cells (hESCs) from emb...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme.10.55
更新日期:2010-07-01 00:00:00
abstract:AIM:It is unknown if the beneficial effects of mesenchymal stromal cells (MSC) transplantation into the liver are dependent on their anchorage and differentiation into hepatocytes or rather the result of the release of stem cell intracellular content with hepatoprotector properties. MATERIALS & METHODS:The effects of ...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme.14.59
更新日期:2015-01-01 00:00:00
abstract::Following the reversal by the court of appeals of the injunction against federal funding of human embryonic stem cell research, Judge Lamberth has held such funding to be lawful and has dismissed the lawsuit. However, the litigation is likely to continue in the court of appeals and ultimately perhaps in the Supreme Co...
journal_title:Regenerative medicine
pub_type: 历史文章,杂志文章
doi:10.2217/rme.11.70
更新日期:2011-11-01 00:00:00
abstract:AIMS:Murine 3T3 feeder cells are commonly used for stem cell expansion. Although 'feeder-free' systems are being developed for a variety of stem cells including embryonic, the use of feeder cells currently remains optimal for the expansion of epithelial stem cells. In this study, MRC-5, a human embryonic fibroblast cel...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/17460751.2.6.919
更新日期:2007-11-01 00:00:00
abstract::Cell therapies aim to repair the mechanisms underlying disease initiation and progression, achieved through trophic effect or by cell replacement. Multiple cell types can be utilized in such therapies, including stem, progenitor or primary cells. This review covers the current state of cell therapies designed for the ...
journal_title:Regenerative medicine
pub_type: 杂志文章,评审
doi:10.2217/rme.14.35
更新日期:2014-01-01 00:00:00
abstract::Genetics Policy Institute (GPI) is a nonprofit, public interest organization recognized as a leading promoter and defender of stem cell research and other cutting-edge medical research targeting cures. Since GPI's inception in 2003, its mission has focused on establishing a positive policy, regulatory and societal fra...
journal_title:Regenerative medicine
pub_type: 新闻
doi:10.2217/rme.09.6
更新日期:2009-05-01 00:00:00
abstract::Pluripotent stem cells (PSCs) can differentiate into virtually any cell type in the body, making them attractive for both regenerative medicine and drug discovery. Over the past 10 years, technological advances and innovative platforms have yielded first-in-man PSC-based clinical trials and opened up new approaches fo...
journal_title:Regenerative medicine
pub_type: 杂志文章,评审
doi:10.2217/rme-2016-0117
更新日期:2016-12-01 00:00:00
abstract::The concept of stem cell therapy has engaged the attention of the public and scientists alike. Intensive research effort is focused upon understanding the biology and therapeutic potential of embryonic and adult stem cells, with the eventual goal of treating such pathologies as Parkinson's disease, diabetes, neurologi...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/17460751.1.5.715
更新日期:2006-09-01 00:00:00
abstract::Promising new medical technologies and approaches to treatment offer the potential to substantially improve the lives of patients who need help, and in some cases transform the way medicine is practiced. In recent years, the biotechnology industry has generated many examples of new approaches that are having a profoun...
journal_title:Regenerative medicine
pub_type: 杂志文章
doi:10.2217/rme.12.90
更新日期:2012-11-01 00:00:00
abstract::Regenerative engineering has been defined as the convergence of Advanced Materials Sciences, Stem Cell Sciences, Physics, Developmental Biology and Clinical Translation for the regeneration of complex tissues and organ systems. Anterior cruciate ligament (ACL) reconstruction necessitates the regeneration of bone, liga...
journal_title:Regenerative medicine
pub_type: 杂志文章,评审
doi:10.2217/rme-2016-0125
更新日期:2016-12-01 00:00:00